Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

@article{Meydan1996InhibitionOA,
  title={Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor},
  author={Naftaly Meydan and Thomas Grunberger and Harjit K. Dadi and Michal Shahar and Enrico Arpaia and Zvi Lapidot and J Steven Leeder and Melvin H. Freedman and Amos Cohen and Aviv Gazit and Alexander Levitzki and Chaim M Roifman},
  journal={Nature},
  year={1996},
  volume={379},
  pages={645-648}
}
ACUTE lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Despite the progress achieved in its treatment, 20% of cases relapse and no longer respond to chemotherapy. The most common phenotype of ALL cells share surface antigens with very early precursors of B cells and are therefore believed to originate from this lineage1,3Characterization of the growth requirement of ALL cells indicated that they were dependent on various cytokines, suggesting paracrine and/or autocrine… 
An investigation into the role of receptor tyrosine kinases in childhood Acute Lymphoblastic Leukaemia
TLDR
The combination of dovitinib or foretinib with conventional cytotoxics demonstrated significant synergy and sensitised steroid – resistant cell lines to dexamethasone, and Objective responses were not identified to single agent TKI therapy in a murine primagraft model.
The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome
TLDR
Results indicate that AG490 exerts a potent inhibitory activity to B-precursor leukemia with specific chromosomal abnormalities, and a therapeutic approach using AG490 is expected.
BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition
TLDR
It is demonstrated that targeted inhibition of BCL6 leads to eradication of drug-resistant and leukaemia-initiating subclones and the discovery of a novel mechanism of drug resistance, which is based on protective feedback signalling ofLeukaemia cells in response to treatment with TKI.
Tyrosine Kinase Inhibitors Suppress the Growth of Non-Hodgkin B Lymphomas
TLDR
A family of PTK inhibitors whose most potent member is AGL 2592 is described, which induces growth arrest and massive apoptosis in a number of non-Hodgkin lymphoma cell lines and is shown to be much more sensitive to this class of agents compared with other malignant carcinoma cells.
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.
TLDR
CGP57148B, a 2-phenylaminopyrimidine derivative, has been shown to selectively inhibit the tyrosine kinase of ABL and BCR-ABL and it is concluded that this new agent may have significant therapeutic applications.
Janus kinase 2: a critical target in chronic myelogenous leukemia.
TLDR
Inhibition of Jak2 by Ag490 treatment resulted in decrease of pSer Akt and c-Myc in imatinib-resistant cells, identifying Jak2 as a potentially important therapeutic target for CML.
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
TLDR
RNAi technology is used to identify a novel oncogenic pathway that involves aberrant activation of the TYK2 tyrosine kinase and its downstream substrate, STAT1, which ultimately promotes T-ALL cell survival through the upregulation of BCL2 expression.
Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia
TLDR
The data show that JAK kinase inhibitors, such as AG490 and WHI-P131 are able to inhibit the STAT1 pathway on B-CLL cells and are strong inductors of apoptosis on these cells.
Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease
TLDR
To overcome resistance to imatinib mesylate, several approaches have been studied in vitro and in vivo, which differ in efficiency, which is often dependent on the mechanisms of resistance.
...
...

References

SHOWING 1-10 OF 31 REFERENCES
Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia.
TLDR
It is shown that IL-7 stimulates DNA synthesis in ALL cells of B-cell precursor as well as immature T-cell origin and is one of the cytokines involved in the complex regulation of ALL cell proliferation.
Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases
TLDR
The B43-Gen immunoconjugate bound with high affinity to BCP leukemia cells, selectively inhibited CD19-associated tyrosine kinases, and triggered rapid apoptotic cell death, which led to 100 percent long-term event-free survival from an otherwise invariably fatal leukemia.
Erythropoietin and interleukin-2 activate distinct JAK kinase family members.
TLDR
It is demonstrated that multiple biochemical pathways are capable of conferring a mitogenic signal in CTLL-EPO-R cells and that the EPO and IL-2 receptors interact with distinct JAK kinase family members within the same cellular background.
Interleukin 7 receptor mediates the activation of phosphatidylinositol-3 kinase in human B-cell precursors.
TLDR
It is demonstrated here that ligation of the IL-7 receptor is associated with increased activity of PI-3 kinase, and by in vivo labeling intact cells, it is shown that IL-6 receptor mediates the activation ofPI-3 Kinase.
Differentiation-linked leukemogenesis in lymphocytes.
TLDR
Characteristics of leukemia and other cancer cells frequently considered to reflect aberrant differentiation may more often reflect clonal selection of cell types that are normally infrequent and transitory.
Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo.
TLDR
The results further support the hypothesis that, on Epo stimulation, JAK2 associates with the membrane-proximal cytoplasmic region of the EpoR to be activated and induces tyrosine phosphorylation of cellular substrates, including theEpoR, to transduce a growth signal.
B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes.
TLDR
The observation that B4 is expressed on almost all early B cell tumors suggests that it may precede B1, CALLA, cytoplasmic mu, and B2 in early B Cell ontogeny.
Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia.
TLDR
The count of residual leukemic progenitor cells is a powerful predictor of relapse after autologous bone marrow transplantation, particularly among male patients and may be useful for analyzing and improving the treatment of patients with high-risk ALL in remission.
Cancer susceptibility in ataxia-telangiectasia.
Ataxia-telangiectasia (A-T) is a syndrome that has an extremely high incidence of cancer. Patients with the disease are homozygous for a mutant gene, the A-T gene, located at 11q23. Of these
...
...